1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31890
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMargalit, Ofer-
dc.contributor.authorHarmsen, William S-
dc.contributor.authorShacham-Shmueli, Einat-
dc.contributor.authorVoss, Molly M-
dc.contributor.authorBoursi, Ben-
dc.contributor.authorWagner, Anna D-
dc.contributor.authorCohen, Romain-
dc.contributor.authorOlswold, Curtis L-
dc.contributor.authorSaltz, Leonard B-
dc.contributor.authorGoldstein, Daniel A-
dc.contributor.authorHurwitz, Herbert-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorKabbinavar, Fairooz F-
dc.contributor.authorAdams, Richard A-
dc.contributor.authorChibaudel, Benoist-
dc.contributor.authorGrothey, Axel-
dc.contributor.authorYoshino, Takayuki-
dc.contributor.authorZalcberg, John-
dc.contributor.authorde Gramont, Aimery-
dc.contributor.authorShi, Qian-
dc.contributor.authorLenz, Heinz-Josef-
dc.date2022-
dc.date.accessioned2023-01-12T04:58:03Z-
dc.date.available2023-01-12T04:58:03Z-
dc.date.issued2023-01-
dc.identifier.citationEuropean Journal of Cancer 2023; 178en_US
dc.identifier.issn1879-0852-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/31890-
dc.description.abstractPrevious studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma (mCRC), showing a benefit in males, while the effect in females is less significant.en_US
dc.language.isoeng-
dc.subjectARCADen_US
dc.subjectAgeen_US
dc.subjectBevacizumaben_US
dc.subjectColorectal carcinomaen_US
dc.subjectMetastaticen_US
dc.subjectSexen_US
dc.titleEvaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean Journal of Cancer (Oxford, England : 1990)en_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.affiliationSheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel.en_US
dc.identifier.affiliationUniversity of Melbourne, Australiaen_US
dc.identifier.affiliationDepartment of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.en_US
dc.identifier.affiliationSheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel.en_US
dc.identifier.affiliationDepartment of Quantitative Science Research, Mayo Clinic, Scottsdale, AZ, USA.en_US
dc.identifier.affiliationDepartment of Oncology, Division of Medical Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.en_US
dc.identifier.affiliationMemorial Sloan Kettering Cancer Centre, New York, NY, USA.en_US
dc.identifier.affiliationRabin Medical Centre, Petach Tikvah, Israel.en_US
dc.identifier.affiliationDuke Cancer Institute, Duke University, Durham, NC, USA.en_US
dc.identifier.affiliationDavid Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.en_US
dc.identifier.affiliationCardiff University and Velindre Cancer Centre, Cardiff, UK.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Franco-British Institute, Levallois-Perret, France.en_US
dc.identifier.affiliationWest Cancer Center, Germantown, TN, USA.en_US
dc.identifier.affiliationDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Japan.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Franco-British Institute, Levallois-Perret, France.en_US
dc.identifier.affiliationDepartment of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.en_US
dc.identifier.affiliationDepartment of Gastrointestinal Oncology, Keck School of Medicine at USC, Los Angeles, CA, USA.en_US
dc.identifier.doi10.1016/j.ejca.2022.10.022en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36446161-
dc.description.volume178-
dc.description.startpage162-
dc.description.endpage170-
dc.subject.meshtermssecondaryBevacizumab/therapeutic use-
dc.subject.meshtermssecondaryColorectal Neoplasms/drug therapy-
local.name.researcherTebbutt, Niall C
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

62
checked on Dec 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.